Adenovirus

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)

Anti-viral T-cell Therapy by Gamma Capture

R-MVST Cells for Treatment of Viral Infections

Viral Specific T-Lymphocytes to Treat Adenovirus or CMV

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

Effectiveness of a Single Dose of Betamethasone in Children With Symptomatic Adenovirus Infection

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

Interest of Rapid Typing in Adenovirus Infections.

Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics